Global Sjogren’s Syndrome Therapeutics Market 2018-2022
About Sjogren’s Syndrome
Sjogren’s syndrome is an autoimmune disorder and the major symptoms of this disorder are dry eyes and dry mouth. The mucous membranes produce reduced tears, and moisture-secreting glands in the mouth secrete smaller amounts of saliva.
Technavio’s analysts forecast the Global Sjogren’s Syndrome Therapeutics Market to grow at a CAGR of 4.12% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the sjogren’s syndrome therapeutics market. To calculate the market size, the report considers the revenue generated from the application of sjogren’s syndrome therapeutics across the globe.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report - Global Sjogren’s Syndrome Therapeutics Market 2018-2022
Technavio recognizes the following companies as the key players in the global sjogren’s syndrome therapeutics market: Allergan, Biogen, Bristol-Myers Squibb, F. Hoffmann-La Roche, and Novartis.
Commenting on the report, an analyst from Technavio’s team said: “One trend affecting this market is the growing development of biologics. Biologic drugs are being increasingly used as monotherapy or as a combination therapy for the treatment of sjogren’s syndrome.”
According to the report, one driver influencing this market is the strong pipeline. The number of molecules in the pipeline for the treatment of sjogren’s syndrome is increasing at a brisk pace which is expected to support the growth of the market.
Further, the report states that one challenge affecting this market is the unwanted immunogenicity. Immunogenicity is a major factor that can limit the growth of the global sjogren’s syndrome therapeutics market across the period of forecast.
F. Hoffmann-La Roche